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PRACTICAL RESEARCH
Impact of a Hospital’s Antibiotic Stewardship 
Team on Fluoroquinolone Use at a Long-
Term Care Facility
Christine L Rahme, PharmD1 • Helen M Jacoby, MD2 • Lisa M Avery, PharmD2,3
The steadily increasing rate of antimicrobial resistance is a major concern in the health care community. In order to combat this threat, hospitals across the nation have successfully implemented antibiotic stewardship 
teams (ASTs). These programs have improved treatment outcomes, limited 
antimicrobial resistance, and decreased the rates of adverse drug events.1 The 
principles of successful ASTs have contributed to the creation of the White 
House’s National Action Plan for Combating Antibiotic-Resistant Bacteria, 
which focuses on improving stewardship in health care settings, including 
long-term care facilities (LTCFs). In combination with the Centers for Disease 
Control (CDC), Centers for Medicare/Medicaid Services (CMS), and Agen-
cy for Healthcare Research and Quality (AHRQ), the National Action Plan, 
which will be executed over 5 years, includes implementing antibiotic steward-
ship programs in LTCFs to decrease the overuse and misuse of antimicrobial 
agents, which result in antibiotic resistance and adverse effects including Clos-
tridium difficile colitis.2 
Antimicrobial agents account for 40% of prescribed medications in LTCFs. 
Additionally, 25–75% of systemic antimicrobial use in LTCFs is reportedly 
inappropriate.3 In the geriatric population, the most common infections in-
clude urinary tract infection (UTI), skin and soft tissue infection (SSTI), and 
respiratory tract infection (RTI). Asymptomatic bacterial colonization may 
result in inappropriate diagnosis of one of these infections, leading to treat-
ment with broad-spectrum antimicrobials such as fluoroquinolones. This class 
of antimicrobials has been associated with an increased risk of Clostridium 
difficile infection (CDI) and multidrug resistant organisms (MDRO).4, 5 One 
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Abstract: The primary objective of this study was to assess whether a hospi-
tal-based antimicrobial stewardship team (H-AST) from an unaffiliated hospital 
could decrease inappropriate fluoroquinolone use at a local, long-term care facil-
ity (LTCF). The H-AST created a multi-faceted intervention campaign that includ-
ed antibiogram development, provider and family education, and a telephone ho-
tline. Pre- and post-intervention mean defined daily doses per 1000 resident days 
for antimicrobials were calculated to determine the impact of the campaign. The 
campaign resulted in a 38.70% decrease in ciprofloxacin utilization, a 16.20% de-
crease in total FQ consumption, and an 11.68% in total antibiotic consumption. 
In addition, during the study period the rate of Clostridium difficile infection de-
creased by 19.47%. Collaboration with a H-AST had a positive impact on antibiot-
ic prescribing at this LTCF.
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commonly employed initiative to decrease CDI rates in 
hospitals is to restrict the use of the fluoroquinolone class 
of antimicrobials.  
With the current lack of antimicrobial stewardship pro-
grams in LTCFs, hospital-based antimicrobial stewardship 
teams (H-ASTs) have the opportunity to improve antimicro-
bial use through collaboration with a local LTCF. Residents 
in LTCFs act as reservoirs for MDRO and CDI, and approx-
imately 20% of hospital admissions are preceded by a LTCF 
transfer or result in a LTCF admission upon discharge.6 The 
transfer of LTCF patients to emergency departments and 
hospitals contributes to the spread of resistance in both in-
stitutions.7  Hospital initiatives to decrease the incidence of 
CDI should take into account this patient sharing. Extend-
ing hospital initiatives to a LTCF that commonly transfers 
patients to that hospital may have a positive effect at both 
institutions. This study assessed the effect of a H-AST on 
the use of fluoroquinolones, overall antibiotic consumption, 
and CDI rates at a neighboring, unaffiliated LTCF. 
The primary objective of this study was to decrease inap-
propriate fluoroquinolone use in a LTCF through education 
and open lines of communication between the H-AST and 
LTCF. Secondary outcomes included decreasing overall an-
tibiotic use in the LTCF by decreasing the treatment rates 
of UTI, RTI, and SSTI, and reducing the rate of CDI. To 
achieve these goals, the H-AST created a multi-faceted in-
tervention campaign which included four major initiatives: 
1) creation of a LTCF urinary antibiogram; 2) an education-
al in-service for providers on appropriate treatment of UTI, 
SSTI and RTI; 3) an educational event specific for family 
members discussing the risks of overusing antimicrobial 
agents; and 4) a telephone hotline for the LTCF to contact 
the H-AST for questions. Pre- and post-intervention mean 
dail defined dose (DDD) per 1000 resident days (RD) data 
for antimicrobials were calculated to determine the impact 
of the campaign.   
Methods
A memorandum of understanding was created between a 
431-bed community teaching hospital and a 520-bed, long-
term, skilled nursing facility. The LTCF medical director, 
nursing manager, and infection prevention nurse collabo-
rated with the H-AST, consisting of infectious disease physi-
cians, an infectious disease pharmacist, a clinical pharmacist, 
the director of pharmacy, the microbiology manager, and 
the infection prevention manager. 
The reference microbiology laboratory provided data on 
urinary pathogen sensitivities from January 2013 to Septem-
ber 2013 based on Clinical and Laboratory Standards Insti-
tute (CLSI) standards.8 The three most commonly isolated 
urinary pathogens were Escherichia coli, Klebsiella pneumo-
nia, and Proteus mirabilis. The antibiogram was distributed 
to the providers via email highlighting the Escherichia coli 
ciprofloxacin sensitivity of 56% (Figure 1). This data was 
also incorporated into the educational campaign.
The education campaign focused on creating treatment 
guidelines for the three most common disease states that af-
fect LTCF residents: UTI, SSTI, and RTI. Supporting litera-
ture was collected and antibiotic treatment recommendations 
were made based on evidence-based medicine, antibiogram 
results, antimicrobial risk of developing CDI, and inci-
dence of adverse effects in the LTCF population. A pocket 
card outlining the recommendations was developed for each 
disease state (Figure 2). In addition, a 60-minute presenta-
tion summarizing treatment recommendations was prepared. 
Highlights of the presentation included the rationale for not 
treating asymptomatic UTI, avoiding the use of fluoroquino-
lones empirically for UTIs based on antibiogram data, differ-
entiating between viral and bacterial respiratory infections, 
discouraging the use of fluoroquinolones for empiric treat-
ment of SSTI, and recommending length of antimicrobial 
therapy for these infections. In addition, common causes of 
altered mental status in the elderly and risk factors for the 
development of CDI were reviewed. The presentation, which 
was given by an infectious disease physician, was attended 
by LTCF physicians, nurse practitioners, physician assistants, 
consultant pharmacists, and administrators. At the conclu-
sion of the educational program, the providers were given a 
telephone number for both the infectious diseases physician 
on call and the antibiotic stewardship pharmacist. They were 
Organism Cipro Levo Gentamicin Tobramycin Doxycycline Bactrim Nitrofurantoin
E Coli
n = 80
56 56 84 92 83 69 89
Proteus
n = 29
55 55 90 95 0 76
0
Figure 1. Urinary Tract Pathogen Antibiogram for Long-Term Care Facility
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Empiric Antibiotic Choice:
Nitrofurantoin (if on Warfarin) or
Bactrim (if not on Warfarin)
Streamlined Antibiotic Choices:
   E. Coli Proteus
1st line Bactrim  
Bactrim
2nd line Nitrofurantoin
3rd line Doxycycline
Women with no catheter:
7 days or
10-14 days  
if severe infection
Men with no catheter: 
10-14 days
Dosing  
Regimens
Renal Function (CrCl) MIC
≥60 ml/min 30-59 ml/min 15-29 ml/min <15 ml/min E Coli Proteus
Bactrim 1 DS tab BID 1 DS tab qday Do not use 69 76
Nitrofurantoin 100 mg BID Do not use if CrCl <40 ml/min 89 0
Doxycycline 100mg BID Do not use 83 0
Criteria for Treatment of a Symptomatic UTI Bacteriuria
Symptoms of a UTI plus Pyuria plus
 A Positive Urine Culture
Symptoms of a UTI:
-Fever and/or Chills
-Otherwise unexplained abrupt change in mental status
-New or increased
• Incontinence
• Flank pain
• Burning or pain during urination
• Frequency 
• Urgency 
 
 
 
Definition: 
Significant bacteria in the urine 
without any signs or symptoms of 
a urinary tract infection
Keep in Mind: Most elderly patients have chronic urinary symptoms such as incontinence, nocturia, 
frequency and/or urgency. In order to be a symptom of a UTI these must change from baseline!
Figure 2. Prescriber Pocket Guide for Urinary Tract Infection  
Abbreviations: UTI, urinary tract infections; DS, double strength; BID, twice a day.
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informed that this number could be called 24 hours a day 7 
days a week for any infectious disease related questions.  
When the LTCF representatives met with the H-AST, 
it was identified that antibiotics are often prescribed in a 
LTCF due to pressure on prescribers by family members. 
This is also well established in other relevant literature.3 To 
address this concern, a 60-minute educational presentation 
titled “To Treat or Not to Treat” was developed for fam-
ily members and presented at one of the monthly family 
council meetings. This was followed by a question and an-
swer session by the infectious disease physician. Similar to 
the provider presentation, topics included UTI, SSTI, RTI, 
and CDI. This presentation included basic true-and-false 
questions to help engage the audience and gauge their base-
line knowledge. For example, the audience was asked: “If 
my family member has bacteria in their urine, should he/
she receive an antibiotic?” In addition, family pamphlets 
were prepared for each of the disease states. Each pamphlet 
clearly explained when the use of antibiotics was deemed 
necessary and the adverse effects associated with inappro-
priate antibiotic use (Figure 2). Written material was re-
viewed by the patient education department at the hospital 
to ensure a reading level of sixth grade or lower. Pamphlets 
were distributed on each care unit in the LTCF.
Data Collection
Pre- and post-intervention data was collected monthly 
from July 2012 to June 2013 and July 2013 to June 2014, 
respectively. Monthly inventory usage reports were gener-
ated by the dispensing pharmacy for all antibiotics pre-
scribed at the LTCF, including doses sent to fill automated 
dispensing cabinets.  For each antibiotic, the total grams 
dispensed were converted to a DDD, as defined by the 
World Health Organization.9 All DDDs were standardized 
per 1000 RD. Pre- and post-intervention mean DDD per 
1000 RD data for ciprofloxacin, levofloxacin, and moxi-
floxacin were calculated. Pre- and post-mean data for total 
antibiotic consumption was calculated and divided by an-
tibiotic class. The infection prevention nurse at the LTCF 
provided monthly totals of RD, as well as rates of UTI, 
SSTI, RTI, and CDI cases per 1000 RD as defined by 
standard CDC definitions.10 
Analysis
Comparison of the 12-month mean DDD per 1000 RD 
pre- and post-intervention for ciprofloxacin, levofloxacin, 
moxifloxacin, fluoroquinolones, penicillins, cephalospo-
rins, macrolides, tetracyclines, nitrofurantoin, sulfon-
amides, and total antibiotic utilization were analyzed using 
a paired t test. The rates of UTI, SSTI, RTI, and CDI from 
the pre- and post-intervention periods were also analyzed 
using a paired t test. Results were determined to be signifi-
cant with a 2-tailed P < 0.05. Analysis was performed using 
IBM® SPSS® Statistics Version 22. A post-hoc analysis was 
performed in June 2015, 12 months after the intervention 
period was over, to determine if the interventions had last-
ing effects on prescribing habits of ciprofloxacin and FQ 
DDD per 1000 RD at the LTCF.  
Results
A significant 38.70% decrease was seen in ciprofloxacin 
utilization in the post-intervention period from 7.08 to 
4.34 DDD per 1000 RD P = 0.02 (Table 1). Levofloxa-
cin and moxifloxacin use did not show a statistically sig-
nificant change, going from 6.16 to 6.72 and 0.34 to 0.32 
DDD per 1000 RD respectively (P = 0.65 and 0.93). Total 
FQ consumption (ciprofloxacin, levofloxacin, and moxi-
floxacin) also did not change significantly, decreasing from 
13.58 to 11.38 DDD per 1000 RD P = 0.31 during the 
intervention period.
Total antibiotic consumption decreased 11.68% from 
82.33 to 72.71 DDD per 1000 RD (P = 0.06) during the 
intervention period. In addition to a 16.20% decrease usage 
in the FQ class, there was also a decrease of 24.49%, 25.34%, 
25.63%, and 14.29% in the cephalosporins, nitrofurantoin, 
macrolides, and tetracycline classes respectively (Table 2). 
Sulfonamide use increased 39.45% from 2.18 DDD per 
1000 RD to 3.04 in the post-intervention period. Post-inter-
vention penicillin usage increased 10.23% comparatively P 
= 0.20. When reviewed at an individual antibiotic level, the 
Table 1. Comparison of 12-month Average DDD/1000 RD FQ Usage Pre- and Post-intervention
Fluoroquinolone
Pre-intervention
DDD/1000 RD
Post-intervention
DDD/1000 RD
% Change P-value (95% CI)
Ciprofloxacin 7.08 ± 2.49 4.34 ± 1.98 - 38.70% 0.02 (0.58 – 4.91)
Levofloxacin 6.16 ± 2.46 6.72 ± 2.41 + 9.09% 0.65 (-3.21 – 2.09)
Moxifloxacin 0.34 ± 0.31 0.32 ± 0.38  - 5.88% 0.93 (-0.32 – 0.34)
Abbreviations: mean DDD/1000 RD, defined daily doses per 1000 resident days; FQ, fluoroquinolone.
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LTCF utilized more amoxicillin (23.70 vs 31.12 DDD per 
1000 RD) and ampicillin (18.9 vs 40.1 DDD per 1000 RD) 
with a decrease in cefuroxime (59.8 vs 50 DDD per 1000 
RD) and ceftriaxone (22.5 vs 9.42 DDD per 1000 RD) in 
the post-intervention period.  
Overall FQ consumption in June of 2015 was 10.03 
DDD per 1000 RD in comparison to 11.38 DDD per 1000 
RD during the intervention period (July 2013-June 2014) 
and 13.58 in the pre-intervention period.
A comparison of infection rates per 1000 RD pre- and 
post-intervention showed a 5.51% decrease in UTI diagno-
sis/treatment from 1.71 to 1.61 (P = 0.28) and a 5.73% de-
crease in RTI from 1.35 to 1.27 (P = 0.67) (Table 3). There 
was an 11.10% increase in the rate of SSTI during the post-
intervention period from 0.92 to 1.04 (P = 0.27). The rate of 
CDI in the LTCF decreased by 19.47% from 0.094 to 0.076 
(P = 0.58) in the post-intervention period. 
Discussion
Our results confirm that the collaboration of a H-AST 
with a LTCF can result in a significant 38.7% decrease in 
ciprofloxacin usage with a decrease trend in overall anti-
biotic usage. Antibiotic stewardship interventions that are 
commonly employed in an acute-care setting such as the 
creation of antibiograms, treatment guidelines, and educa-
tional materials are not readily available in LTCF. The use 
of a H-AST team to fill this gap in the LTCF setting and 
provide microbiology data, provider education, and a 24-
hour hotline, as done in this study, is a novel concept. 
The four initiatives employed by the H-AST had the big-
gest impact on ciprofloxacin prescribing. The LTCF anti-
biogram results showed that only 56% of facility E coli were 
susceptible to ciprofloxacin, providing clear evidence that 
ciprofloxacin is an inappropriate agent for empiric therapy 
of a symptomatic UTI in this population. In addition, both 
the provider and family educational campaign focused on 
decreasing inappropriate prescribing for asymptomatic bac-
teriuria in the LTCF population. With these initiatives, the 
H-AST was able to decrease the treatment rate of UTI by 
5.51% in the post-intervention period, which may have 
also contributed to the decrease in ciprofloxacin use.  The 
H-AST was not able to significantly decrease levofloxacin or 
moxifloxacin prescribing.
In addition, the interventions to decrease ciprofloxacin 
prescriptions resulted in a decrease in overall antibiotic 
consumption and a shift in antibiotic classes prescribed at 
the LTCF. Overall antibiotic consumption in the LTCF de-
creased by 11.68%. Although this decrease did not quite 
reach statistical significance (P = 0.06), the trend is promis-
ing. One of the main goals of the H-AST was to educate 
prescribers and patient families on the risks of treating as-
ymptomatic bacteriuria and viral infections. Studies on the 
inappropriate treatment of these disease states in the elderly 
population have shown an increase risk of MDRO and an-
timicrobial adverse effects, without a change in morbidity 
and mortality.11,12 The number of reported cases of UTI and 
RTI decreased during the intervention period but did not 
reach statistical significance. Treatment guidelines and edu-
cational sessions reinforced shorter treatment courses for 
UTI, RTI, and SSTI, which may have also contributed to 
the decrease in overall antibiotic use at the LTCF.   
The H-AST also had an impact on promoting antimi-
crobial classes with a lower incidence of causing CDI. Over 
the 12-month period, there was a decrease in cephalosporin, 
tetracycline, and macrolide prescribing with an increase in 
the use of agents in the penicillin and sulfonamide classes. 
Table 2. Comparison of 12-month Average DDD/1000 RD for Separate Antibiotic Classes and Total 
Antibiotic Usage Pre- and Post-intervention
Antibiotic Class
Pre-intervention
DDD/1000 RD
Post-intervention
DDD/1000 RD
% Change P-value (95% CI)
Penicillins 19.26 ± 5.79 21.23 ± 4.92 + 10.23% 0.20 (-5.15 – 1.21)
Cephalosporins 12.78 ± 4.56 9.65 ± 2.26 - 24.49% 0.06 (-0.15 - 6.41)
Macrolides 6.36 ± 2.60 4.73 ± 2.86 -25.63% 0.24 (-1.25 – 4.50)
Tetracyclines 22.33 ± 9.70 19.14 ± 4.88 - 14.29% 0.29 (-3.10 – 9.48)
Fluoroquinolones 13.58 ± 3.50 11.38 ± 4.07 - 16.20% 0.31 (-2.38 – 6.78)
Sulfonamides 2.18 ± 1.06 3.04 ± 1.40 + 9.45% 0.13 (-2.02 – 0.30)
Nitrofurantoin 1.97 ± 1.17 .47 ± 0.64 -25.34% 0.22 (-0.34 – 1.33)
Total Antibiotic Use 82.33 ± 12.23 72.71 ± 6.80 - 11.68% 0.06 (-0.44 – 19.67)
Abbreviations: mean DDD/1000 RD, defined daily doses per 1000 resident days. 
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During the post-intervention period, broad-spectrum cepha-
losporins, such as ceftriaxone and cefuroxime, decreased by 
13.08 and 9.8 DDD per 1000 RD, while penicillins, such as 
amoxicillin and ampicillin, increased by 7.42 and 21.2 DDD 
per 1000 RD. The increase in aminopenicillins in the post-
intervention period may have been the result of promoting 
these agents for the treatment of nonpurulent cellulitis during 
the educational campaign as recommended in current SSTI 
guidelines from the Infectious Disease Society of America.13 
This therapy may have replaced the use of cephalosporins or 
the inappropriate use of fluoroquinolones for SSTI. The use 
of sulfamethoxazole-trimethoprim also increased in the post-
intervention group by 39.45%. The provider education ses-
sions highlighted the use of sulfamethoxazole-trimethoprim 
as a first-line option for the empiric treatment of UTIs (Fig-
ure 2) as well as Staphylococcal skin infections. Despite the 
significant decrease in ciprofloxacin use, decrease in overall 
antibiotic consumption, and shift away from high-risk CDI 
inducing antibiotics, there was not a statistically significant 
decrease in the rate of CDI. This is likely due to the fact that 
CDI rates at the institution were already reasonably low. 
LTCF providers and nursing staff commonly state that 
a large obstacle to appropriate antimicrobial prescribing is 
family pressure. Providing family member education was a 
unique element to this stewardship initiative. Providing an 
education session with a question-and-answer period and 
providing easy-to-read pamphlets (Figure 3) throughout the 
facility, explaining the harm of inappropriate prescribing, 
may have contributed to a decrease in family member pres-
sure on medical and nursing staff, overall antibiotic use, and 
treatment rates for UTI and RTI.
Other LTCF initiatives that have been reported to de-
crease inappropriate antimicrobial prescribing have included 
education, prescriber feedback, nursing audit, guideline de-
velopment, and infectious disease physician consultation.14-18 
One initiative studied the effect of printed educational ma-
terial in conjunction with periodic physician scorecards on 
adherence to the treatment guidelines for UTI, RTI, SSTI, 
and septicemia of unknown origin over a 9-month period.16 
Education and prescribing feedback significantly decreased 
non-adherent prescribing by 64% (odds ratio 0.35 95%; CI 
0.18-0.73) at the 6-month follow-up, but this significance 
was not maintained at the 9-month interval. Another initia-
tive provided a UTI treatment algorithm to LTCF physicians 
and nurses along with written material consisting of pocket 
cards, posters, real-time reminders, and outreach visits.17 For 
that initiative, there was a statistically significant decrease in 
the proportion of total antibiotics prescribed for UTI in the 
intervention group compared to the paired controls 28% 
to 39% (weighted mean difference, -9.6%; range, -16.9 to 
-2.4%), although there was no significant change in urinary 
cultures obtained, hospitalization, or mortality between 
groups. Similar to the previous study, the impact of educa-
tion was not maintained at the 12-month post-intervention. 
In our study, the H-AST collected data 12 months after the 
intervention period (June 2105) to assess the durability of 
the effect on FQ consumption. One year following the inter-
vention, FQ use had declined further, from 11.38 DDD per 
1000 RD at the end of the intervention to 10.03.
Previous studies have shown that decreasing the use of 
fluroquinolone antibiotics results in lower CDI rates.19,20 A 
community hospital decreased their rate of CDI from 1.6 to 
1.2 cases per 1000 RD by restricting FQ usage from 17.6 to 
6.0 DDD per 1000 RD in addition to implementing envi-
ronmental cleaning procedures. The baseline rate of CDI at 
the LTCF where our study was conducted was low, prevent-
ing us from showing a statistically significant decline in CDI 
rates, however, the measured rate did decline from 0.094 to 
0.076 post-intervention. In addition, it is unknown what the 
effect of decreasing CDI rates in a LTCF has on the transfer-
ring hospital.  
Controlling the use of fluoroquinolones in a LTCF may 
also have an impact on the incidence of the NAP-1/027/B1 
strain of CDI.21 Fluoroquinolones are known to single out 
the NAP-1/027/B1 strain that can be associated with greater 
toxin production and more severe disease, especially in the 
Table 3. Comparison of Infection Rates per 1000 RD Pre- and Post-intervention
Infection Pre-Intervention Post-Intervention % Change value (95% CI)
UTI 1.71 ± 0.21 1.61± 0.24 - 5.51% 0.28 (-0.088-0.28)
RTI 1.35 ± 0.47 1.27 ± 0.44 - 5.73% 0.67 (-0.31 – 0.46)
SSTI 0.92 ± 0.19 1.04 ± 0.33 +11.10% 0.27 (-0.33 – 0.10)
CDI 0.094 ± 0.09 0.076 ± 0.59 -19.47% 0.58 (-0.053 – 0.090)
Abbreviations: RD, resident days; UTI, urinary tract infection; RTI, respiratory tract infection; SSTI, skin and soft tissue infection; 
CDI, Clostridium difficile infection.
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elderly population.22 A prevalence study showed that hospital 
patients admitted from a LTCF were four times more likely 
to be infected with this strain than patients admitted from 
home.22 It is unknown if the decrease in FQ usage had an ef-
fect on the occurrence of the NAP-1 strain at the LTCF, since 
this data was unavailable from the microbiology laboratory.  
Despite the ability to collect monthly antibiotic usage 
data, the lack of electronic medical records at the LTCF made 
it difficult to track the exact indication for FQ use. The an-
tibiotic usage data were captured by pharmacy dispensing 
data. This may not have accurately captured doses received 
since the dispensing pharmacy did not credit doses that were 
not administered. In addition, the use of DDD in the el-
derly population may over-predict usage as these patients are 
commonly on lower, total daily doses based on reduced re-
nal function. Infection data were evaluated using definitions 
of UTI, SSTI, and RTI as reported by the infection control 
nurse at the institution and may have included patients with 
non-infectious or viral causes. These definitions, however, 
were consistent throughout the study period. An additional 
limitation was that the number of phone calls made from 
the LTCF to the on-call physician and pharmacist were not 
documented during the study period. Finally, the LTCF per-
formed environmental changes during the pre-intervention 
period that could have affected the CDI rates during the 
post-intervention period. 
This study was not able to identify the potential impact of 
antibiotic stewardship in a LTCF on the hospital, although it 
is anticipated to be beneficial. Future research needs to focus 
on the impact of transitions in care on CDI and MDRO 
in LTCF patients. During collaborative meetings with the 
LTCF providers, it was identified that patients transferred 
to the hospital’s emergency department with confusion or 
delirium were inappropriately prescribed antimicrobials, in-
cluding ciprofloxacin, and then sent back to the LTCF to 
complete the therapy. To help combat this issue, the H-AST 
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provided an interactive, case-based in-service to the emer-
gency department (ED) providers on patients transferred 
from the LTCF to the ED with asymptomatic UTIs after 
the intervention period was completed. This reiterates the 
importance of recognizing the impact of transition of care on 
inappropriate antimicrobial prescribing. Future research also 
needs to focus on education programs for LTCF nursing staff 
and consultant pharmacists on the appropriate prescribing of 
antimicrobials in this population.  
Conclusion
A minimal resource education campaign at a LTCF performed 
by a H-AST was able to have a large impact on decreasing cip-
rofloxacin prescribing for UTI and asymptomatic bacteriuria 
with a statistically significant decrease in ciprofloxacin con-
sumption by 37.7% over a 12-month period. This may have 
contributed to a decreased incidence of CDI by 19.47%. In 
2011, the AHRQ Healthcare Cost and Utilization Project es-
timated that 21.5% of hospital discharges of older adults were 
either preceded by a LTCF transfer or resulted in admission 
to a LTCF.6 This high patient flow amongst institutions rep-
resents a large risk for the transmission of MDRO including 
CDI. With this influx, H-ASTs would be advised to focus on 
more than just antimicrobial use within the hospital walls. u 
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